MiR-873 Regulates ERα Transcriptional Activity and Tamoxifen Resistance via Targeting CDK3 in Breast Cancer Cells by Cui, J. et al.
Indiana University - Purdue University Fort Wayne
Opus: Research & Creativity at IPFW
Chemistry Faculty Publications Department of Chemistry
Fall 12-22-2014
MiR-873 Regulates ERα Transcriptional Activity
and Tamoxifen Resistance via Targeting CDK3 in
Breast Cancer Cells
J. Cui
Department of Cancer and Cell Biology, University of Cincinnati College of Medicine, Cincinnati, OH, USA; Institute of Disease
Control and Prevention, Chinese Academy of Military Medical Sciences, Beijing , China;
M. Bi
Department of Cancer and Cell Biology, University of Cincinnati College of Medicine, Cincinnati, OH, USA
A. Overstreet
Department of Cancer and Cell Biology, University of Cincinnati College of Medicine, Cincinnati, OH, USA
Y. Yang
Department of Neurobiology, Beijing Institute for Neuroscience, Capital Medical University, Beijing , China
H. Li
4 Department of Molecular and Biomedical Pharmacology, University of Kentucky College of Medicine, Lexington, KY, USA
See next page for additional authors
This research is a product of the Department of Chemistry faculty at Indiana University-Purdue University
Fort Wayne.
Follow this and additional works at: http://opus.ipfw.edu/chemistry_facpubs
Part of the Biological Phenomena, Cell Phenomena, and Immunity Commons, and the
Chemistry Commons
This Article is brought to you for free and open access by the Department of Chemistry at Opus: Research & Creativity at IPFW. It has been accepted
for inclusion in Chemistry Faculty Publications by an authorized administrator of Opus: Research & Creativity at IPFW. For more information, please
contact admin@lib.ipfw.edu.
Opus Citation
J. Cui, M. Bi, A. Overstreet, Y. Yang, H. Li, Y. Leng, K. Qian, Q. Huang, C. Zhang, Z. Lu, J. Chen, R. Wu, Y. Sun, H. Hong, X. Wei, Peng
Jing, A. Meredith, X. Yang, and C. Zhang (2014). MiR-873 Regulates ERα Transcriptional Activity and Tamoxifen Resistance via
Targeting CDK3 in Breast Cancer Cells. Oncogene. 1-13. London, UK: Nature Publishing Group.
http://opus.ipfw.edu/chemistry_facpubs/95
Author(s)
J. Cui, M. Bi, A. Overstreet, Y. Yang, H. Li, Y. Leng, K. Qian, Q. Huang, C. Zhang, Z. Lu, J. Chen, R. Wu, Y.
Sun, H. Hong, X. Wei, Peng Jing, A. Meredith, X. Yang, and C. Zhang
This article is available at Opus: Research & Creativity at IPFW: http://opus.ipfw.edu/chemistry_facpubs/95
ORIGINAL ARTICLE
MiR-873 regulates ERα transcriptional activity and tamoxifen
resistance via targeting CDK3 in breast cancer cells
J Cui1,2, M Bi2, A-M Overstreet2, Y Yang3, H Li4, Y Leng5, K Qian5, Q Huang6, C Zhang7, Z Lu1, J Chen8, T Sun8, R Wu1, Y Sun1, H Song1,
X Wei9, P Jing10, A Meredith2, X Yang2 and C Zhang1
miRNAs (microRNAs) are frequently and aberrantly expressed in many cancers. MiR-873 has been revealed to be downregulated in
colorectal cancer and glioblastoma. However, its function remains unclear. Here we report that miR-873 is downregulated in breast
tumor compared with normal tissue. Enforced expression of miR-873 decreases the transcriptional activity of ER (estrogen
receptor)-α but not ERβ through the modulation of ERα phosphorylation in ER-positive breast cancer cells. We also found that
miR-873 inhibits breast cancer cell proliferation and tumor growth in nude mice. Reporter gene assays revealed cyclin-dependent
kinase 3 (CDK3) as a direct target of miR-873. CDK3 was shown to be overexpressed in breast cancer and phosphorylate ERα at
Ser104/116 and Ser118. Furthermore, we found that Mir-873 inhibits ER activity and cell growth via targeting CDK3. Interestingly,
miR-873 was observed to be downregulated in tamoxifen-resistant MCF-7/TamR cells, while CDK3 is overexpressed in these cells.
More importantly, re-expression of miR-873 reversed tamoxifen resistance in MCF-7/TamR cells. Our data demonstrate that miR-873
is a novel tumor suppressor in ER-positive breast cancer and a potential therapeutic approach for treatment of tamoxifen-resistant
breast cancer.
Oncogene advance online publication, 22 December 2014; doi:10.1038/onc.2014.430
INTRODUCTION
Breast cancer is the most common type of cancer and one of the
leading causes of cancer-related death in women worldwide. The
estrogen receptor (ER), which has a prominent role in breast
cancer, is a member of the nuclear receptor superfamily of ligand-
activated transcription factors.1,2 There are two different forms of
the ER, α and β, each encoded by a separate gene (ESR1 and
ESR2, respectively).3 On binding estrogen, the ER undergoes
conformational changes and binds to the estrogen response
elements (ERE), which are located on the upstream sequences
of estrogen-responsible genes such as TFF1 and c-Myc.4,5 The ER
protein is a composite of multiple domains including a DNA-
binding domain and two major transcriptional activation function
(AF) domains, AF-1 and AF2. The AF1 domain located in the N
terminus is a ligand-independent transactivation domain. Its
function can be enhanced by phosphorylation through the
mitogen-activated protein kinase and AKT pathways. The AF-2
domain located in the C terminus has a ligand-dependent
function.6–8 Similar to other nuclear receptors, ER regulates target
genes by recruiting transcriptional co-regulators and components
of the basal transcription machinery. The ligand-bound ER,
depending on the nature of the ligand, recruits and interacts
with co-regulatory proteins that can either enhance (co-activators)
or repress (co-repressors) it’s transcriptional activity.9–12
Approximately 70% of breast cancers are ER positive and the
majority fully depends on estrogen signaling. Thus, disruption of
ER function is the main therapeutic strategy employed in targeting
the disease.2,13 The selective ER modulator, tamoxifen, can bind to
the ER and block the interaction between estrogen and the ER.
Tamoxifen has been the mainstay of endocrine therapy in both
early and advanced breast cancer patients for almost three
decades.14–16 Unfortunately, it is known that not all patients with
ER-positive breast cancer respond to tamoxifen (known as de novo
resistance). Moreover, many patients that receive tamoxifen as
adjuvant therapy eventually acquire tamoxifen resistance
(acquired resistance). Thus, tamoxifen resistance, either de novo
or acquired, presents a major challenge in treating breast
cancer.17–21
MicroRNAs (miRNAs) are 20- to 22-nucleotide-long noncoding
RNAs. They mostly anneal in the 3′-untranslated region (UTR) of
protein-coding mRNAs leading to posttranscriptional silencing of
their respective genes. It is becoming increasingly evident that
miRNAs are key modulators of breast cancer initiation and
progression. miRNAs can function as oncogenes or tumor
suppressor genes depending on their gene targets.22,23 A recent
METABRIC (Molecular Taxonomy of Breast Cancer International
Consortium) study has provided a system-level analysis of miRNA
expression proﬁles across a large number of human breast tumors
and revealed oncogenic and tumor-suppressive roles of
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differential miRNAs.24 More than 10 miRNAs were found to target
ERα and its co-regulators that regulate ERα transcriptional
activities.25 Several recent studies have revealed the roles of
miRNAs in tamoxifen resistance. Speciﬁcally, miR-221/222 was
able to confer resistance to tamoxifen, potentially owing to their
large gene-targeting spectrum.26 Genome-wide miRNA microarray
analysis revealed that miRNA-375 was among the top down-
regulated miRNAs in tamoxifen-resistant cells. Re-expression of
miR-375 was sufﬁcient to sensitize resistant cells to tamoxifen and
partly reversed epithelial to mesenchymal transition via directly
targeting the oncogene, metadherin.27
We screened several poorly understood miRNAs, which have
been reported to be downregulated in cancer, and found that
miR-873 is downregulated in breast tumor compared with normal
tissue. MiR-873 has been shown to be downregulated in colorectal
cancer and glioblastoma; however, its function has not been
reported.28,29 Here we found that miR-873 could inhibit ERα
phosphorylation and its transcriptional activity via targeting
cyclin-dependent kinase 3 (CDK3). MiR-873 was shown to have
an important role in breast cancer cell proliferation and tumor
growth. We also revealed that mir-873 regulates tamoxifen
resistance in breast cancer cells.
RESULTS
MiR-873 regulates ER signaling in breast cancer cells
According to the databases of recent studies, several miRNAs with
unknown functions have shown reduced expression in many
types of human cancer.24,28,30 In order to screen novel miRNAs,
which are downregulated in breast cancer, we performed real-
time PCR to investigate the expression of selected miRNAs. As a
result, four miRNAs were found to be downregulated in breast
cancer compared with normal tissue. Among four miRNAs
identiﬁed, miR-873 expression was reduced by more than ninefold
compared with normal tissue (Supplementary Table S1).
Estrogen signaling and the ER have a pivotal role in breast
cancer initiation and progression, and the majority of human
breast cancers start out as estrogen dependent.1,2 To investigate
the role of miR-873 in ER signaling, the expression plasmid for
miR-873 or control vectors were co-transfected with ERE-Luc into
breast cancer cells. We used real-time PCR to validate that the
transfection of miR-873 signiﬁcantly elevated miR-873 levels in
both MCF-7 and SKBR3 cells (Figure 1a). As shown in Figure 1b,
overexpression of miR-873 inhibited luciferase reporter activities
in both the absence and presence of estrogen in MCF-7 cells.
Interestingly, miR-873 signiﬁcantly decreased reporter activity in
response to the ERα-speciﬁc agonist propylpyrazole triol but not
to the ERβ-speciﬁc agonist, diarylpropionitrile. These results
indicate that miR-873 inhibits ERα but not ERβ transcriptional
activity. To verify the speciﬁc effect of miR-873 on ERα, we co-
transfected ERα or ERβ plasmids with miR-873 in ERα- and ERβ-
negative SKBR3 breast cancer cells. Consistent with the results in
MCF-7, miR-873 speciﬁcally inhibited ERα transcriptional activity
only (Figure 1c).
To determine whether endogenous miR-873 is involved in ER
transactivation, we used anti-miR-873 inhibitor to diminish
miR-873 expression in MCF-7 cells. As expected, the anti-
miR-873 inhibitor oligo effectively inhibited miR-873 expression,
whereas the control oligo had no effect (Figure 1d). As shown in
Figure 1e, suppression of the normal expression of miR-873 in
MCF-7 cells signiﬁcantly enhanced the ERα transcriptional activity.
Moreover, we also examined the effect of miR-873 on several
well-known endogenous ERα target genes. We found that
overexpression of miR-873 inhibited TFF1 and c-Myc expression
at both the mRNA (Figure 1f) and protein (Figure 1g) levels. To
investigate how miR-873 decreases transactivation of ERα, we
examined the effect of miR-873 on ERα expression and its
phosphorylation level. In the absence or presence of E2, enforced
expression of miR-873 did not alter ERα expression. However,
overexpression of miR-873 inhibited phosphorylation of S118 but
not S167 (Figure 1h). We then performed chromatin immunopre-
cipitation to investigate the effect of miR-873 on the occupancies
of ERα and its co-activators. As a result, enforced expression of
miR-873 inhibited the recruitments of ERα and its co-activators
(CBP, MED1 and AIB1) to TFF1 and c-Myc promoter (Figure 1i and
Supplementary Figure S1).
MiR-873 inhibits cell growth in vitro and in vivo
Our above data indicated a key role for miR-873 in ERα-mediated
transcription. Thus, we further assessed the role of miR-873 in the
growth of ER-positive breast cancer cells. We ﬁrst performed cell
proliferation assays on cells, which stably expressed miR-873.
Overexpression of miR-873 signiﬁcantly diminished cell prolifera-
tion of MCF-7 and ZR75-1 cells (Figure 2a and Supplementary
Figure S2), while suppression of miR-873 in MCF-7 cells
signiﬁcantly enhanced cell proliferation (Figure 2b). Next, we
determined the role of miR-873 in anchorage-independent colony
formation using a soft agar assay. We found that overexpression of
miR-873 signiﬁcantly reduced the number and size of the colonies
formed (Figures 2c and d).
To conﬁrm whether the biological effects of miR-873 observed
in cultured cells are relevant to tumor growth in vivo, stable
miR-873-overexpressing cells were injected into nude mice. As
shown in Figures 2e and f, overexpression of miR-873 reduced
tumor size and weight when compared with control groups. The
expression of miR-873 in tumors was conﬁrmed by reverse
transcription–PCR (data not shown). Taken together, these data
indicate that miR-873 has an important role in the growth of
breast cancer cells, both in vitro and in vivo.
MiR-873 directly targets CDK3
To understand the mechanisms by which miR-873 inhibits ERα
signaling, several computational methods were used to help
identify miR-873 targets in humans. As miR-873 reduced ERα
Figure 1. MiR-873 regulates ER signaling in breast cancer cells. (a) Real-time PCR analysis of miR-873 level in MCF-7 and SKBR3 cells transfected
with miR-873-expressing or control vector. (b and c) MiR-873 inhibited ERα transcriptional activity. MCF-7 (b) and SKBR3 (c) cells were
transfected with control vector or pCDH-miR-873, along with plasmids expressing ERE-TK-LUC reporter and PRL-TK (internal control)-, ERα- or
β-expressing plasmids, followed by vehicle, E2, propylpyrazole triol (PPT) or diarylpropionitrile (DPN) treatment for 24 h. The relative luciferase
values are expressed as mean± s.e. (d) Real-time PCR analysis of miR-873 level in MCF-7 cells transfected with anti-miR-873 or control oligo. (e)
MCF-7 cells were transfected with anti-miR-873 or control oligo, along with plasmids expressing ERE-TK-LUC reporter and PRL-TK (internal
control), followed by vehicle, E2, PPT or DPN treatment for 24 h. The relative luciferase values are expressed as mean± s.e. (f and g) MiR-873
inhibited ERα target gene expression. MCF-7 cells were infected with lentivirus containing miR-873 or control vector, followed by real-time
reverse transcription–PCR (f) and western blotting (g) analyses of ERα target gene expression. (h) MiR-873 inhibited ERα S118 phosphorylation.
MCF-7 cells were infected with lentivirus containing miR-873 or control vector, followed by western blot analyses of ERα phosphorylation
level. (i) MiR-873 inhibited the recruitments of ERα and its co-activators. MCF-7 cells were infected with lentivirus containing miR-873 or
control vector, followed by chromatin immunoprecipitation, to detect the recruitments of ERα and its co-activators (*Po0.05, **Po0.01,
miR-873 versus control plasmid under the same treatment).
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phosphorylation, we hypothesized that its potential targets
should include kinases. Among those potential targets, CDK3
is of particular interest because its homolog, CDK2, was
previously implicated in phosphorylating ERα and enhancing its
transcriptional activity. Therefore, we decided to carry out a series
of experiments to determine whether CDK3 is a direct target of
miR-873. First, we detected the effect of miR-873 on CDK3
expression. Although miR-873 overexpression did not change
MiR-873 inhibits ER signaling
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CDK3 mRNA levels, there was a clear reduction in CDK3 protein
levels in MCF-7 and T47D cells (Figures 3a and b). However,
miR-873 silencing caused an increase in CDK3 protein levels in
MCF-7 and T-47D cells (Figure 3c). As a control, miR-873 did not
affect CDK2 protein expression. These ﬁndings suggest that
miR-873 targets CDK3 through translational inhibition. Next, we
generated wild-type and mutant CDK3-3′-UTR expression plas-
mids that were fused to a luciferase reporter according to the
matched sequence between CDK3-3′-UTR and miR-873
(Figure 3d). We found miR-873 overexpression signiﬁcantly
inhibited luciferase activity of wild-type but not mutant reporter
genes in MCF-7 and T47D cells (Figure 3e and Supplementary
Figure S3a). However, miR-873 silencing speciﬁcally enhanced the
luciferase activity of wild-type but not mutant CDK3-3′-UTR
(Figure 3f and Supplementary Figure S3b).
In order to study the correlation of miR-873 and CDK3 in breast
cancer, we performed real-time PCR and western blotting using 20
patient samples and 5 adjacent noncancerous tissues. A negative
correlation between miR-873 and CDK3 was observed in the
breast cancer samples (Figure 4).
CDK3 phosphorylates ER and enhances ER activity
It has been shown that CDK2 phosphorylates ERα and enhances its
transcriptional activity.31 As CDK3 has high homology with CDK2,
we deduced that CDK3 also interacts and phosphorylates ERα. In
order to examine this possible interaction between CDK3 and ERα,
Figure 2. MiR-873 inhibits cell growth in vitro and in vivo. (a) MTT assay of cell growth in MCF-7 cells, which stably expressed miR-873. (b) MTT
assay of cell growth in MCF-7 cells, which were transfected with anti-miR-873 oligo. (c and d) Six thousand miR-873 cells/well stably expressing
MCF-7 cells were mixed with 0.35% agarose and plated in a six-well plate. The resulting colonies were photographed (c) after 3 weeks
incubation and quantiﬁed (d). (e) miR-873 inhibited tumor growth in a human breast cancer MCF-7 xenograft mouse model. Cells stably
expressing MiR-873 or control cells were injected into nude mice and each group included eight mice. The tumor volume represents the
mean± s.e. (f) Tumor weights were calculated and shown as a box plot with median and whiskers from minimum to maximum (*Po0.05,
miR-873 versus control plasmid under the same treatment).
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N-terminally FLAG-tagged, full-length CDK3 and MYC-tagged ERα
were expressed in HEK293T cells and treated with estrogen. FLAG-
CDK3 was immunoprecipitated from cell lysates by an anti-FLAG
antibody and analyzed for ERα binding by western blot analysis.
As shown in Figure 5a, ERα was co-immunoprecipitated and
detected in the presence and absence of estrogen. This result
demonstrates that CDK3 interacts with ERα in vivo in a ligand-
independent manner.
To ascertain the interaction of CDK3 with ERα in a more
physiological context, the endogenous CDK3 protein from MCF-7
cells was immunoprecipitated with anti-CDK3 antibody. Subse-
quent blotting with anti-ERα antibody indicated that the
endogenous CDK3 interacted with ERα (Figure 5b). Next, we
performed reverse co-immunoprecipitation in MCF-7 cells and
conﬁrmed the interaction between these two proteins
(Supplementary Figure S4). Finally, we performed glutathione S-
transferase (GST) pull-down assay and the result showed that
CDK3 directly interacts with ERα (Figure 5c).
To determine whether CDK3 phosphorylates ERα, we performed
a kinase assay and detected ERα phosphorylation using phos-
phorylation site-speciﬁc antibodies of ERα. As shown in Figure 5d,
GST-ERα but not GST was phosphorylated at three sites: Ser104,
106 and 118. Next, we carried out experiments using MCF-7 cells
to ascertain the effect of CDK3 on ERα phosphorylation. As shown
in Figure 5e, we found that knockdown of CDK3 signiﬁcantly
decreased ERα phosphorylation at Ser104, 106 and 118 in MCF-7
cells. These results indicate that CDK3 phosphorylates ERα at
Ser104, 106 and 118. To determine the biological signiﬁcance of
ERα phosphorylation by CDK3, we examined ERα activity with an
ERE-luciferase reporter gene assay in MCF-7 cells. Knockdown of
CDK3 by speciﬁc short hairpin RNA (shRNA) led to a signiﬁcant
decrease of ER activity (Figure 5f).
CDK3 is overexpressed in breast cancer and positively regulates
breast cancer cell proliferation
It has been reported that CDK3 is overexpressed in human
glioblastoma tissue and enhances cell transformation.32 To
investigate whether CDK3 is overexpressed in human breast
cancer, we carried out a tissue microarray using anti-CDK3
antibody. We found that CDK3 exhibited a very low level in
normal breast tissues, yet it was overexpressed in breast cancer
tissues (Figures 6a and b). Next, we detected CDK3 expression in
breast cancer cells and found that compared with normal breast
cell MCF-10A, CDK3 has a higher protein level in breast cancer
cells (Figure 6c).
To study the effects of CDK3 on cell proliferation, we infected
MCF-7 and ZR75-1 cells with lentivirus-expressing control
scramble or CDK3 shRNA, and measured cell proliferation by
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
Figure 3. CDK3 is a direct target of miR-873. (a) Real-time PCR analysis of CDK3 mRNA level in MCF-7 and T47D cells infected with miR-873-
expressing or control vector. (b) Western blot analysis of CDK3 protein levels in MCF-7 and T47D cells infected with miR-873-expressing or
control vector. (c) Western blot analysis of CDK3 protein level in MCF-7 and T47D cells transfected with anti-miR-873 or control oligo. (d) Gene
structure of CDK3 showing the predicted target site of miR-873 in its 3′-UTR. (e and f) MCF-7 cells were transfected with reporter gene
containing wild-type (3′UTR-WT) or mutant (3′UTR-Mu) CDK3 3′-UTR along with miR-873 or control vector (e), anti-miR-873 or control oligo
(f) as indicated (*Po0.05).
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assay after control vehicle or estrogen treatments. As shown by
western blot analyses (Figure 6d), CDK3 shRNA treatment
successfully knocked down CDK3 protein expression in both cell
lines. Importantly, we found that CDK3 knockdown signiﬁcantly
inhibited MCF-7 and ZR75-1 cell proliferation, as compared with
scramble shRNA-treated cells (Figures 6e and f).
MiR-873 inhibits ER activity and cell growth via targeting CDK3
To further explore whether CDK3 is a functional target of miR-873,
we re-introduced the CDK3 coding sequence without the 3′-UTR
through lentivirus infection into cells stably overexpressing
miR-873. Western blots showed that CDK3 lentivirus infection
restored CDK3 expression, which was inhibited by miR-873 in
MCF-7 cells (Figure 7a). We then measured ERα transcriptional
activity and found that re-expression of CDK3 diminished the
inhibitory effect of miR-873 on ERα transcriptional activity
(Figure 7b). We also found that overexpression of CDK3 restored
the recruitments of ERα and its co-activators, which were inhibited
by miR-873 (Supplementary Figure S5). Real-time PCR assays
showed that overexpression of CDK3 could restore ER target
genes such as TIFF1 and c-Myc expression, which were inhibited
by miR-873 (Figure 7c). In addition, we also found that knockdown
of CDK3 signiﬁcantly decreased ER target gene expressions
(Supplementary Figure S6). We further investigated whether
miR-873 inhibits cell proliferation via targeting CDK3. As a result,
we found that overexpression of CDK3 diminished the inhibitory
effect of miR-873 on cell proliferation. Soft agar assays also
suggested that overexpression of CDK3 could restore cell
transformation, which was inhibited by miR-873 in MCF-7 cells
(Figures 7d and e).
MiR-873 regulates tamoxifen resistance in breast cancer cells via
targeting CDK3
Several studies have demonstrated that direct inhibition of cyclin-
dependent kinases may overcome the problem of resistance to
anti-estrogen treatments in breast cancer.33,34 We decided to carry
out experiments to investigate whether miR-873/CDK3 could
regulate tamoxifen resistance in breast cancer cells. To address
this possibility, we generated the tamoxifen-resistant cell line
MCF-7/TamR. Resistance of the cells to tamoxifen was veriﬁed by
cell viability assays (Supplementary Figure S7). We then investi-
gated miR-873 and CDK3 expression in MCF-7/TamR cells. As
shown in Figures 8a and b, compared with parental MCF-7 cells,
miR-873 was present at lower levels in MCF-7/TamR cells,
while CDK3 was present at signiﬁcantly higher levels in MCF-7/
TamR cells. We next investigated whether miR-873 could be
involved in tamoxifen resistance in MCF-7/TamR cells. For this
purpose, MCF-7/TamR cells were stably transfected with
either control or miR-873 expression vectors, and treated
with or without tamoxifen. Enforced expression of miR-873
was capable of sensitizing MCF-7/TamR cells to tamoxifen.
Importantly, transfection of CDK3 reversed the effect of
miR-873 on tamoxifen resistance in MCF-7/TamR cells
(Figure 8c). In addition, knockdown of CDK3 was also capable
of sensitizing MCF-7/TamR cells to tamoxifen (Supplementary
Figure S8).
Previous studies have shown that tamoxifen has an agonist role
on ERα-mediated transcription in tamoxifen-resistant cells.18,35 To
determine the effect of miR-873 on ERα transcriptional activity and
estrogen-responsive gene expression in response to tamoxifen,
we decided to carry out a series of experiments. In agreement
with previous studies, we found that tamoxifen could induce ERα
transcriptional activity in MCF-7/TamR cells. We also found that
Figure 4. Expression analysis of miR-873 and CDK3 in human breast cancer. Breast tumor and adjacent normal tissues were used to study
miR-873 and CDK3 expressions via real-time PCR (a) and western blotting (b). Their expressions were normalized and their expression
correlation was analyzed by correlation coefﬁcient and t-test (c).
MiR-873 inhibits ER signaling
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overexpression of miR-873 could inhibit ERα transcriptional
activity by tamoxifen treatment in MCF-7/TamR cells. More
importantly, transfection of CDK3 could abolish this tamoxifen-
induced ERE reporter gene inhibition by miR-873 (Figure 8d).
Along with this, we also examined the effects of miR-873 on
tamoxifen-induced expression of endogenous ERα target genes in
MCF-7/TamR cells. As shown in Figure 8e, our results indicate that
miR-873 inhibited tamoxifen-induced expression of ERα target
genes. We also examined the potential effect of miR-873 on the
recruitments of the co-repressors N-CoR and SMRT, as they have
been shown to have important roles in the anti-proliferative action
of tamoxifen.10,11,36 As expected, tamoxifen failed to recruit N-CoR
and SMRT in tamoxifen-resistant cells. However, tamoxifen was
shown to recruit N-CoR and SMRT in MCF-7 cells (Supplementary
Figure S9). Enforced expression of miR-873 effectively restored the
recruitments of N-CoR and SMRT by tamoxifen to TFF1 promoter
(Figure 8f).
To determine the role of miR-873 on tamoxifen resistance
in vivo, cells stably expressing miR-873 were injected into nude
mice and then these mice were treated with tamoxifen. As
expected, tamoxifen treatment alone did not signiﬁcantly alter
tumor growth compared with vehicle control group in mice
injected with MCF-7/TamR cells. However, tamoxifen treatment
could further potentiate tumor growth inhibition by miR-873
Figure 5. CDK3 interacts and phosphorylates ERα. (a) FLAG-tagged CDK3 and MYC-tagged ERα or empty vectors were co-transfected into
HEK293T cells. Cell lysates were immunoprecipitated (IP) by anti-FLAG M2 monoclonal antibody and the precipitates were then
immunoblotted with anti-MYC antibody. (b) MCF-7 cells were treated with and without 10 nM E2 for 1 h. Cell lysates were immunoprecipitated
with either anti-CDK3 antibody or control IgG. The precipitates were analyzed by western blotting using anti-ERα. (c) Direct interaction of
CDK3 with ERα. Glutathione-Sepharose beads bound with GST-ERα (1-282) or with GST were incubated with the lysates of MCF-7 cells, which
were transfected with FLAG-CDK3. After washing the beads, the bound proteins were analyzed by western blotting using anti- FLAG antibody.
(d) CDK3 phosphorylates c-Jun at Ser104/106 and 118. An in vitro kinase assay was conducted with active CDK3 and GST-ERα (1-282).
Phosphorylation of ERα at Ser104/106 and Ser118 was analyzed using phospho-speciﬁc antibodies and western blotting. (e) MCF-7 cells were
infected with lentivirus expressing scramble or CDK3 shRNA and then treated with E2 or vehicle. ERα phosphorylation level was detected
using phospho-speciﬁc antibodies as indicated. (f) MCF-7 cells were transfected with CDK3 shRNA or scramble shRNA, along with plasmids
expressing ERE-TK-LUC reporter and PRL-TK, followed by vehicle or E2. The relative luciferase values are expressed as mean± s.e. (*Po0.05,
CDK3 shRNA versus scramble under the same treatment).
MiR-873 inhibits ER signaling
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(Figure 8g). These results suggest that miR-873 sensitizes breast
cancer cells to tamoxifen in vivo.
DISCUSSION
High-throughput sequencing revealed that miR-873 is down-
regulated in colorectal cancer and glioblastoma, but its role in
cancer has not been determined.28,29 In this study, we have
investigated the role of miR-873 as a negative regulator of both
ER-mediated transcription and breast cancer cell growth. Initially,
we demonstrated that miR-873 inhibits the transcriptional activity
of ERα but not ERβ, thereby modulating estrogen-responsive
genes. MiR-873 was also found to inhibit the proliferation of breast
cancer cells and tumor growth in vitro. We then noted that
miR-873 decreases ERα Ser118 phosphorylation and ERα recruit-
ments on ERE sequences. Our data also showed that miR-873
directly targets CDK3 (CDK3 can phosphorylate ERα and enhance
its transcriptional activity). Lastly, we found that miR-873 is further
downregulated in tamoxifen-resistant cells and re-expression of
miR-873 can restore tamoxifen sensitivity. Taken together, these
ﬁndings support a key role for miR-873 in breast cancer
development and tamoxifen resistance.
Studies have shown that miRNAs may function as oncogenes or
tumor suppressors in many cancers, depending on which genes or
pathways they regulate.22,23 miRNAs have been implicated in
almost all aspects of cancer biology, including proliferation,
apoptosis, invasion, metastasis, angiogenesis and drug
resistance.37–39 New technical developments such as small RNA
high-throughput sequencing have revealed novel cancer-related
miRNAs. Using this kind of sequencing, miRNAs, such as miR-873,
having unknown function were found to be signiﬁcantly down-
regulated in the glioblastomas.29 In colorectal cancer, high-
resolution chromatin immunoprecipitation-seq revealed that
miR-873 is epigenetically silenced.28 A recent METABRIC study
has described the miRNA proﬁle in breast cancer.24 Consistent
with the METABRIC study, miR-873 was shown to be down-
regulated in breast cancer through a reverse transcription–PCR
screen in our study. Our study further demonstrated over-
expression of MiR-873 inhibits breast cancer cell proliferation
and tumor growth in nude mice. These ﬁndings along with
previous studies indicate that miR-873 may function as a common
tumor suppressor.
Mechanistically, the downregulation of miR-873 in ER-positive
breast cancer may suggest that miR-873 has an important role in
ER signaling regulation.24 Indeed, we found that miR-873
speciﬁcally inhibits ERα but not ERβ transcriptional activity and
decreases ERα phosphorylation level. Several miRNAs have been
implicated in disrupting ER activity through targeting the ER or its
co-regulators.25 To our knowledge, this is the ﬁrst study to report
that an miRNA can regulate the ER phosphorylation level. Indeed,
ER phosphorylation has an important role in breast cancer
initiation and tamoxifen resistance. Thus, this study provides an
alternative mechanism to regulate ER signaling for miRNAs.
Endocrine resistance remains a major challenge in the ﬁeld of
breast cancer. Recent studies have revealed roles of miRNAs in
tamoxifen resistance. Downregulation of miR-375 and miR-451 are
Figure 6. CDK3 is overexpressed in breast cancer and required for cell proliferation. (a and b) CDK3 expression in breast cancer was detected
using a tissue microarray containing 10 normal and 43 cancer tissues. Representative images of CDK3 immunohistochemistry staining of
human breast cancer samples (a) and statistical analysis (b) are shown. (c) Western blot analysis of CDK3 protein levels in breast cancer cells as
indicated. (d) Western blot analyses of CDK3 levels in MCF-7 and ZR75-1 cells after control scramble or CDK3 shRNA treatments. (e and f)
Control or CDK3 shRNA-knockdown MCF-7 cells (e) or ZR75-1 cells (f) were treated with vehicle (Veh) or an indicated amount of E2. Cells were
then collected and assessed for cell proliferation by MTT assays (*Po0.05, CDK3 shRNA versus scramble under the same treatment).
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associated with tamoxifen resistance in breast cancer and re-
expression of miR-375 reverses tamoxifen resistance.27,40 How-
ever, miR221/222 is upregulated in both tamoxifen-resistant cells
and patients, and confers resistance to tamoxifen via targeting
p27.26 In this study, we revealed a role of miR-873 in tamoxifen
resistance. MiR-873 was found to be downregulated in tamoxifen-
resistant cells and re-expression of miR-873 restored the sensitivity
of cells to tamoxifen. Our data also indicated that miR-873
functions in tamoxifen resistance via targeting CDK3. As miR-221-
/222 targets p27, an inhibitor of CDK3, it is very interesting to
study their expression relationship and whether they cooperate in
tamoxifen resistance in breast cancer. In addition, we have
investigated the effect of miR-873 on CDK3 expression in MDA-
MB-231 and SKBR3 cells. Overexpression of miR-873 reduced
CDK3 expression by 1.9- and 2.4-fold, respectively (data not
shown). This suggests that targeting of CDK3 by miR-873 is not
speciﬁc in ER-positive breast cells but miR-873 exhibits a much
stronger effect on regulating CDK3 expression in ER-positive
compared with ER-negative breast cancer cells.
There are two possible mechanisms for miR-873 to be involved
in tamoxifen resistance. MiR-873 may inhibit ER phosphorylation
at Ser104/106 and 118 via targeting CDK3, which would restore
the sensitivity of resistant cells to tamoxifen. These phosphoryla-
tion sites on the ER have been implicated to have an important
role in tamoxifen resistance.41,42 A second mechanism for miR-873
could be due to the restoration of tamoxifen-induced recruitments
of N-CoR and SMRT on ERE. Transcriptional co-repressors N-CoR
and SMRT have been shown to have important roles in the anti-
proliferative action of tamoxifen in breast cancer cells.10,11,36 In the
presence of tamoxifen, ERα is known to preferentially bind and
recruit the transcriptional co-repressors N-CoR and SMRT to target
gene promoters. The anti-proliferative effect of tamoxifen
depends on the recruitment of these co-repressors. However,
ERα fails to recruit N-CoR and SMRT in tamoxifen-resistant cells.18
Thus, recruitment restoration of N-CoR and SMRT is very important
to overcome tamoxifen resistance. Interestingly, there is a possible
linkage between ERα phosphorylation and co-repressor recruit-
ments. It has been reported that in a tamoxifen-resistant cell line
ERα S118 phosphorylation was found to be elevated, and ligand-
independent activation of ERα through phosphorylation of S118
may contribute to tamoxifen resistance.41,43,44 Another study
showed that phosphorylated S118 decreases ERα afﬁnity for
tamoxifen and reduces its binding to DNA in the presence of
tamoxifen.45 This may subsequently lead to reduced co-repressor
recruitments by ERα in the presence of tamoxifen.
CDKs are key regulators of the cell cycle.46 In many human
cancers, CDKs are overactive or CDK-inhibiting proteins are not
functional.47,48 Compared with other members of the CDK family,
little is known about CDK3. Although CDK3 is closely related to
CDK2, it is not required for cell cycle progression in normal cells.
Figure 7. MiR-873 inhibits ER transcriptional activity and cell growth via targeting CDK3. (a) Western blot analyses of CDK3 protein levels after
infecting with lentivirus expressing CDK3 into MCF-7 cells, which stably expressed miR-873. (b) Cells described in a were transfected with
plasmids expressing ERE-TK-LUC reporter and PRL-TK (internal control), followed by vehicle or E2 treatment for 24 h. The relative luciferase
values are expressed as mean± s.e. (c) Cells described in a were treated with vehicle or E2 for 24 h and subjected to real-time PCR, to detect
ERα target gene expressions as indicated. (d) Cells described in a were treated with vehicle or E2 for 24 h and subjected to MTT assay, to detect
cell growth. (e) Soft agar assay were performed in cells described in a. The resulting colonies were photographed (left panel) after 3 weeks
incubation and quantiﬁed (right panel) (*Po0.05, miR-873 versus control plasmid under the same treatment).
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This is based on its low expression in human tissue and
spontaneous mutational inactivation in the germline of laboratory
mice.49 In cancer cell lines and tumor tissues, CDK3 is
overexpressed.32,50 The gene for CDK3 has been mapped to
chromosome 17q22-qter telomeric to the BRCAl locus, which is
associated with chromosome rearrangement in breast cancer. This
rearrangement results in deregulation of CDK3 gene expression or
the production of an abnormal transcript of CDK3 in MDA-MB-543
cells.51 Indeed, we found that CDK3 is hardly detectable in normal
breast tissue but exhibits a higher level in breast cancer tissue.
Figure 8. Overexpression of miR-873 sensitizes resistant cells to tamoxifen treatment. (a) Real-time PCR analysis of miR-873 levels in MCF-7 and
MCF-7/TamR cells. (b) Western blot analysis of CDK3 protein levels in MCF-7 and MCF-7/TamR cells. (c) MCF-7/TamR cells were infected with
lentivirus expressing CDK3 in MCF-7/TamR cells, which stably express miR-873, and then treated with an indicated amount of
4-hydroxytamoxifen (TAM) for 7 days. Cells were then collected and assessed for cell proliferation by MTT assays. (d) Cells described in c
were transfected along with plasmids expressing ERE-TK-LUC reporter and PRL-TK (internal control) followed by vehicle (Veh) or E2 treatment
for 24 h. The relative luciferase values are expressed as mean± s.e. (e) MCF-7/TamR cells, which stably express miR-873 or control plasmid,
were treated with vehicle (Veh) or 4-hydroxytamoxifen (TAM) for 24 h, and TFF1 and c-Myc gene expressions were detected by real-time PCR.
(f) Cells described in e were treated with Veh or TAM for 1 h, and N-CoR and SMRT recruitments on TFF1 promoter were detected by chromatin
immunoprecipitation assay. (g) MCF-7/TamR cells, which stably expressed miR-873, or control plasmids were injected into nude mice. After
2 weeks, mice were injected with Veh or TAM, and tumors were measured with Vernier calipers at the indicated times. Each group included six
mice. (*Po0.05, miR-873 versus control plasmid under the same treatment).
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This tumor selectivity distinguishes CDK3 as a cancer target
from cell cycle-regulating CDKs (CDK1, CDK2, CDK4 and CDK6).
CDK3-selective inhibitor SNX9 class compounds have been
approved as a patent (number EP20070809083) and clinical trials
studying it efﬁcacy are underway (https://www.sbir.gov/sbir
search/detail/370403). In this study, we found that miR-873
regulates ER activity and tamoxifen resistance via targeting
CDK3 but not CDK2. This ﬁnding suggests a cross-talk between
ER signaling and CDK3. Based on this, one potential treatment
option could be a combination of tamoxifen and a CDK3 inhibitor,
which would work synergistically to prevent ER-positive cell
proliferation.
Palbociclib, a small molecule inhibitor of CDK4 and CDK6, has
shown considerable efﬁcacy in ER-positive breast cancer cell lines
and xenograft models. Combinations of palbociclib with tamox-
ifen have proven to be synergistic in ER-positive cell lines.34
Studies are needed to test the effects of SNX9 class compounds in
ER-positive breast cancer and the synergistic effect of its
combination with tamoxifen.
Apparently, one miRNA may regulate many genes as its targets,
while one gene may be targeted by many miRNAs. Thus, miR-873
is very likely to regulate other genes simultaneously to inhibit
breast tumor growth. In addition, CDK3 can also be targeted by
other miRNAs than miR-873. We postulated that one signal axis
such as miR-873/CDK3 has a critical role in speciﬁc cellular
signaling and its function in breast cancer depends on the genetic
context. Despite multiple relationships, our data provide solid
evidences that the miR-873/CDK axis has an important role in
breast cancer cell growth and tamoxifen resistance in breast
cancer cells. Thus, we strongly believe that targeting this pathway
may be a potential therapeutic approach for the treatment of ER-
positive breast cancer.
MATERIALS AND METHODS
Cell culture
The human breast cancer cell lines MCF-7, ZR75-1, T47D, SKBR3, MDA-
MB-231 and HEK293T were purchased from American type culture
collection (ATCC, Manassas, VA, USA). Cell lines were authenticated on
the basis of viability, recovery, growth and morphology. The expression
status of ER was further conﬁrmed by western blotting before they were
used in the experiments. All cells were cultured in Dulbecco’s modiﬁed
Eagle’s media medium containing 10% fetal bovine serum (Hyclone,
Thermo Fisher Scientiﬁc, Florence, KY, USA) at 37 °C with 5% CO2 in tissue
culture incubators. 17β-estradiol (E2) and 4-hydroxytamoxifen (TAM) were
purchased from Sigma (St Louis, MO, USA). Tamoxifen-resistant cells
(MCF-7/TamR) were developed by culturing tamoxifen-sensitive MCF-7
cells in the presence of 1 μM TAM for more than 1 year. For experiments
involving E2 or TAM treatments, cells were routinely cultured in phenol
red-free Dulbecco’s modiﬁed Eagle’s media plus 10% charcoal-stripped
fetal bovine serum for at least 3 days before the treatments.
Plasmids and lentiviral vector preparation
The plasmid pERE-TK-Luc, pRL-CMV and scramble shRNA expression
constructs were described previously.35 To generate lentiviral constructs,
miR-873 (Gene ID: 100126316) and CDK3 (Gene ID: 1018) genes were
separately generated by PCR ampliﬁcation and the PCR products were
then cloned into pCDH-CMV (System Biosciences, Mountain View, CA,
USA). High-titer lentivirus were generated by transient transfection of
HEK293T cells. Anti-miR-873 inhibitor and control oligonucleotides were
purchased from Invitrogen (Carlsbad, CA, USA).
Generation of stable cell lines
Cells were infected with lentivirus containing miR-873 and monoclonal cell
lines were generated using 2 μg/ml puromycin (Sigma). In order to restore
CDK3 expression in miR-873-overexpressed cell line, we treated these cells
with lentivirus containing CDK3 and seeded cells in a 96-well plate with 1–
2 cells in each well. Two to three months later, CDK3 and miR-873
expressions were detected by real-time PCR and western blotting using
CDK3 antibody (Sigma). Primers for miR-873 were purchased from Exiqon
(Vedbaek, Denmark).
Transient transfections and reporter gene assays
For transfection, cells were plated in 24-well plates containing Phenol Red-
free RPMI 1640 medium supplemented with 10% charcoal-stripped fetal
bovine serum, and the plasmids were transfected with Lipofectamine 2000
(Invitrogen). Following transfection, the cells were treated with E2 or TAM
for 24 h and then collected for the dual luciferase assay. The dual luciferase
reporter assay system (Promega, Madison, WI, USA) was employed to
measure the luciferase activity.
Real-time PCR
Total RNA was isolated from cells with an Rneasy Mini kit (Qiagen, Hilden,
Germany) or Trizol (Invitrogen) reagent, according to the manufacturer’s
instructions. Total RNA from each sample was reverse transcribed with
oligo(dT)20 using SuperScript III Reverse Transcriptase (Invitrogen) followed
by real-time PCR. Primers for miR-873 were purchased from Exiqon. Primer
sequences for TFF1 and c-Myc were described previously.52 Real-time PCR
was performed with SYBR Green PCR Master Mix reagents using an ABI
Prism 7700 Sequence Detection System (Applied Biosystems, Foster City,
CA, USA).
Chromatin immunoprecipitation
Chromatin immunoprecipitation analysis was performed as described
previously.53 In brief, MCF-7 and MCF-7/TamR cells were treated for 45min
with vehicle (ethanol), 100 nM E2 or 1 μM TAM, and immediately ﬁxed by
adding 37% formaldehyde to the medium, to a ﬁnal concentration of 1%.
After washing with phosphate-buffered saline, cells were collected with
lysis buffer. The nuclear lysates were sonicated to generate an average
DNA size of 0.5–1 kb, and then immunoprecipitation was performed with
anti-ERα, anti-N-CoR or anti-SMRT (Santa Cruz Biotechnology, Dallas, TX,
USA). Real-time PCR ampliﬁcation was performed with DNA extracted from
the immunoprecipitates. The primers for TFF1 and c-Myc promoter were
described previously.52
MTT assay
MTT (Sigma-Aldrich, Saint Louis, MO, USA) assay was performed as
described previously, with minor modiﬁcations.52 Cells were seeded and
treated with vehicle, E2 or TAM as indicated. MTT was added to the
medium to a ﬁnal concentration of 0.5 mg/ml and then the medium was
removed and 0.2 ml DMSO was added. After incubation for 30min in room
temperature, the absorbance of the converted dye was measured at
570 nm using a Synergy spectrophotometer.
Soft agar assay
For anchorage-independent growth, 5 × 103 cells were plated on six-well
plates containing a bottom layer of 0.6% low-melting-temperature agar in
Dulbecco’s modiﬁed Eagle’s media and a top layer of 0.3% agar in
Dulbecco’s modiﬁed Eagle’s media. Colonies were scored and photo-
graphed after 3 weeks of growth.
Co-immunoprecipitation
Co-immunoprecipitation assay was performed as described previously.54 In
brief, cells were treated with 10 nM E2 or vehicle for 1 h. Cells were
collected and lysed in 0.5 ml lysis buffer (50mM Tris, pH 8.0, 250mM NaCl,
0.25% NP-40, 1 mM dithiothreitol and protease inhibitor tablets from Roche
(Penzberg, Germany) and immunoprecipitation was performed with anti-
FLAG M2 afﬁnity gel, anti-CDK3 (Sigma), anti-ERα (Cell Signaling
Technology, Danvers, MA, USA) or anti-MYC (Santa Cruz Biotechnology).
The beads were washed and resolved by SDS–polyacrylamide gel
electrophoresis, followed by immunoblotting.
GST pull-down assay
ERα 1-282 was inserted into the Pgex-4T1 vector and expressed as GST-
fusion proteins in Escherichia coli strain BL21 and bound to glutathione-
Sepharose beads puriﬁed as described by the manufacturer (Amersham
Biosciences, Piscataway, NJ, USA). The expression plasmids FLAG-CDK3
were transfected into HEK293T cells and the cell lysate was incubated with
about 1 μg of GST alone or GST-ERα 1-282 fusion protein bound to
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glutathione-Sepharose beads in 500 μl of binding buffer (50 mM Tris-HCl,
pH 7.4, 100mM NaCl, 5 mM MgCl2, 0.1% Nonidet P-40, 10% glycerol, 1 mM
dithiothreitol and protease inhibitor tablets from Roche Applied Science
(Penzberg, Germany) at 4 °C or 6 h. The beads were precipitated, washed
three times with binding buffer and subjected to SDS–polyacrylamide gel
electrophoresis and western blotting using anti-FLAG antibody (Sigma).
Kinase assay
An in vitro kinase assay was conducted with active Cdk3 and GST-ERα (1-
282) fusion protein according to a previous study.55 Brieﬂy, lysates of cells
stably transfected with Cdk3 were subjected to immunoprecipitation with
Cdk3 antibody. The immune complex was incubated with GST-ERα (1-282)
fusion protein at 30 °C for 30min and then resolved by 12% SDS–
polyacrylamide gel electrophoresis. ERα phosphorylation at Ser104/106
and Ser118 was analyzed by western blotting using phospho-speciﬁc
antibodies. Phospho-ERα-S104/106, S118 and anti-ERα antibodies were
purchased from Cell Signaling Technology.
Immunohistochemistry staining
Immunohistochemistry staining of human breast cancer tissue microarray
(Superchip, Shanghai, China) was carried out essentially as previously
described.35 In brief, the slide was ﬁrst deparafﬁnized and subjected to
heat-induced antigen retrieval using citrate buffer. The tissue sections were
then incubated with primary antibodies against CDK3 (Abcam, Cambridge,
MA, USA) overnight at 4 °C, followed by extensive washes. The slide was
subsequently treated with biotinylated anti-rabbit secondary antibody and
then developed using avidin-conjugated horseradish peroxidase with
diaminobenzidine as the substrate. Hematoxylin was used for counter-
staining and the images were visualized and captured using Axioplan
Imaging 2e microscope (Carl Zeiss, Oberkochen, Germany).
Human tissue analysis
Breast tumor and adjacent noncancerous tissues were obtained from the
Afﬁliated Hospital of Jiujiang University, with the informed consent of
patients and with approval for experiments from the Afﬁliated Hospital of
Jiujiang University. Tissue samples were used for RNA and protein
extraction to examine miR-873 and CDK3 expressions.
Animal experiments
MCF-7 or MCF-7/TamR cells (1 × 107) that stably expressed miR-873 or
control plasmids were injected into the abdominal mammary fat pad of 6-
week-old female nude mice. When tumors reached the volume of ~ 100
mm3, we randomly allocated the mice to groups in which they received
placebo or tamoxifen pellets (Innovative Research of America, Sarasota, FL,
USA). Tumor growth was monitored by caliper measurements. Excised
tumors were weighed and portions were frozen in liquid nitrogen. All the
experimental procedures involving animals were conducted in accordance
with Institutional Animal Care guidelines and approved ethically by the
Administration Committee of Experimental Animals, Institute of Disease
Control and Prevention, Chinese Academy of Military Medical Sciences,
Beijing, China. The protocol number is IACUC-2013035.
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